Unsupported price increase report: 2020 assessment
- Collection:
- Health Policy and Services Research
- Author(s):
- Rind, David M., author Agboola, Foluso, author Chapman, Richard, author Borrelli, Eric, author McKenna, Avery, author Pearson, Steven D., author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, January 12, 2021
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Drug Costs -- statistics & numerical data Health Expenditures -- statistics & numerical data United States
- Genre(s):
- Technical Report
- Abstract:
- The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. Despite these initiatives, there had been no systematic approach at a state or national level to determine whether certain price increases are justified by new clinical evidence or other factors. In 2017, the Institute for Clinical and Economic Review (ICER) sought and received funding from Arnold Ventures to develop ICER Unsupported Price Increase (UPI) Reports to determine whether new clinical evidence or other information has appeared that could support the price increases of those drugs with recent, substantial price increases that have had the largest impact on national drug spending. This is the second of these reports.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918231204606676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918231204606676